Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data
FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July 29.
Capricor's medicine for a muscle disease is being questioned by FDA experts before an important review meeting on July 29. When experts raise questions about whether a medicine really works, it can make people nervous about the company's chances of getting approval.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.